Advances In™: Meeting Unmet Clinical Needs in AML with Evolving Therapeutic Approaches
View More
ACCC 40th National Oncology Conference Pre-Session: Clinical Updates from Chicago – A Focus on What Community Centers Need to Know to Move Their Solid Tumors' Practices Forward
Register Now!
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Antibody-Drug Conjugates in Gynecological Cancer – Setting the Stage
View More
Reflective Case-Based Oncology Collective: Real-World Applications of Novel Therapies Across TNBC and Addressing Disparities in Care
View More
Catching Them Early: A Real-World Case Discussion on the Application of Testing Methodologies to Identify Key Markers Across NSCLC
View More
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Register Now!
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
OTX-2002 Shows Encouraging Safety in Small Hepatocellular Carcinoma Cohort
Most adverse effects appear to be grade 1 or 2 among patients with hepatocellular carcinoma and other solid tumors associated with the MYC oncogene receiving OTX-2002 in the phase 1/2 MYCHELANGELO I trial.
Pomalidomide Combo Yields PFS/OS Benefits in R/R Multiple Myeloma
Pomalidomide plus bortezomib and dexamethasone confers a larger progression-free survival benefit than bortezombib plus dexamethasone among patients with relapsed/refractory multiple myeloma in the phase 3 OPTIMISMM trial.
Novel Drugs May Introduce ‘New Era’ of Metastatic Prostate Cancer Treatment
Neeraj Agarwal, MD, states that he is optimistic about the development of new treatment options including immunotherapies, CAR T-cell therapies, and antibody-drug conjugates for metastatic prostate cancer.
Daratumumab Combos Are Effective in NDMM Despite Relapses in Subgroups
APOBEC mutational activity appears to be prognostic in patients with newly diagnosed multiple myeloma or precursor diseases who receive daratumumab quadruplets, according to Kylee Maclachlan, MBChB, PhD.
Real-world Teclistamab Use Finds Comparable Efficacy With MajesTec-1 in Multiple Myeloma
September 29th 2023When teclistamab was evaluated in a real-world setting, investigators determined that efficacy was similar between that and the phase 2 MajesTec-1 trial for patients with relapsed/refractory multiple myeloma.
Data Confirm Dara-KRd/Double Transplant Benefit in Newly Diagnosed Myeloma
September 29th 2023Investigators report a low rate of high-grade hematologic adverse effects following treatment with induction Dara-KRd and consolidation double transplant in patients with high-risk, newly diagnosed multiple myeloma.
FDA Clears Chromogranin A Immunoassay in Gastroenteropancreatic NETs
Clearance of an automated immunoassay allows practices to measure chromogranin A concentration in human serum, thereby tracking disease progression in those with gastroenteropancreatic neuroendocrine tumors.